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Abstract
Poor adherence to medication regimens is responsible for 30-70% of all medicationrelated hospital admission in the United States and can be calculated to cost approximately $100
billion per year (Burra et al., 2011). The purpose of this pre-post cohort analysis is to measure
the impact of using a mobile phone application and text messaging service on the medication
possession ratio (MPR), a measure of adherence, among solid organ transplant patients who fill
at Nebraska Medicine Outpatient Pharmacy. These interventions make it more convenient for
patients to request refills, for pharmacy staff to send push notifications, and automatic refill
and/or pickup reminders to be generated. Higher medication adherence rates to
immunosuppressive agents, along with all other medications, promote better long-term outcomes
such as: longevity of transplanted organ and prevention of adverse events. I hypothesize a
positive association between the use of a mobile phone application and/or text messaging service
and the MPR. 59 patients were identified in pharmacy software, McKesson, that had voluntarily
used the mobile phone application and/or text messaging service prior to 6/12/2020. Each
patient’s MPR was manually derived for one year before intervention (6/12/2019-6/11/2020) and
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one year after intervention (6/12/2020-6/12/2021). MPR is the sum of the days’ supply for all
fills of a given drug in a particular time period, divided by the number of days in the time period
(1 year). The sample characteristics were examined and reported in terms of type of transplant,
sex, race, and age. Then t-tests were conducted to examine if MPR is associated with age, sex,
race, or type of transplant at baseline, one-year pre-intervention, and one-year post-intervention.
Then, a multiple linear regression was run to examine if there were significant change in patient
MPR over the two years after controlling age, sex, race, and type of transplant in the model. The
results of the two-tailed, paired t-test comparing the average MPR in year 2020-2021 to that of
year 2019-2020 returned a p-value of 0.31, indicating no statistically significant differences
between these two years. This result does not support our hypothesis that the use of a mobile
phone application and/or text messaging service will increase the MPR of solid organ transplant
patients. In conclusion, analyzing the effect of the same intervention on a larger patient
population with a lower baseline MPR, such as diabetic patients, would be more powerful using
the same pre-post study design.
Introduction
Specific Aims or Problem Statement:
The specific aims of this project are to analyze if the implementation of text messaging
and/or mobile phone application is increasing the MPR in solid organ transplant recipients that
fill their immunosuppressant medications at the Nebraska Medicine Outpatient Pharmacy. The
analysis of this project will be used to present information to the Transplant Pharmacists at
Nebraska Medicine to show the interventions that our pharmacy can provide on increasing
medication adherence to immunosuppressant regimens. Patient safety and positive patient
outcomes are at the forefront of this project and healthcare in general. Medication adherence
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promotes graft function, prevents graft rejection, prevents hospital admissions and decreases
financial burden on the healthcare industry as a whole.
Significance:
Adherence is a crucial component of transplant patients’ therapeutic regimen. According
to Adherence to Long-Term Therapies: Evidence for Action, adherence “refers to the extent to
which a person’s behavior—taking medication, following a diet, and or executing lifestyle
changes, corresponds with the agreed recommendations from a health care provider (Sabate,
2003).” Immunosuppression nonadherence carries a risk of graft rejection and potential graft
loss. Poor adherence to medication regimens is responsible for 30-70% of all medication-related
hospital admission in the United States and can be calculated to cost approximately $100 billion
per year (Burra et al., 2011).
More than 165,000 apps designed for smartphones are related to health, and 1 in 5 people
have downloaded a mobile health app (Perez-Jover et. al, 2019). Among those subsets of
downloaded mobile health apps, many help patients manage their chronic disease states and their
medication management. For example, reminding users to take medications and providing tools
on how to be adherent. Other than medication administration reminders, these apps can provide
refill reminders, doses can be logged, data logs that can be accessed by patients or uploaded to
care providers, and readily available medication information.
Background and Literature Review
Background on Mobile Phone Application:
Patients could voluntarily opt-in to the text message service prior to 6/12/2020, however,
after this date patients were pre-enrolled and a link with directions was sent via text message on
how to download the mobile application if a cell phone number was uploaded in McKesson
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pharmacy software. Patients can download the mobile application in the following ways: (1) text
“APP” to 54053, (2) search “Nebraska Medicine Pharmacy” in the iPhone App Store or Google
Play Store, (3) using the website
https://nebraskamed.medrefill/nmweb[nebraskamed.medrefill.com, patients can enter their cell
phone number in the “get a text to download our mobile app” section, and (4) by scanning the
QR Code on print materials at Point-of-Sale. Setting up an account on the mobile application
allows the patient to fully manage their text message preferences. Additionally, patients can see
all their prescriptions in one place and refill them by scanning their prescription or choosing
from the list provided in the application. Reminders can be set to both refill medications and take
medications. The mobile application and web portals allow patients to manage prescriptions on
behalf of their family members. Downloading the mobile application gives patient access to print
an expense report of their full prescription history at their convenience.
Real time text messages to patients are critical to maintain adherence. All of the text
messages will include contact information for the pharmacy if they have any additional questions
and/or concerns. If a patient chooses to sign up to receive text messages, they will be notified
during the following points in the prescription process: (1) when their prescription is due to be
refilled (patients have the ability to reply back and request their refill to be processed), (2) when
their prescription is ready (including the copayment amount due), (3) when their prescription has
been shipped to them (including the tracking number), (4) a reminder that their prescription is at
the pharmacy waiting to be picked up, (5) a reminder when their prescription has not yet been
picked up and will soon be returned to sock. In addition to the automated messages, pharmacy
staff has the ability to send push text messages in specific circumstances to make it easier to
communicate with patients. Some examples of messages include: (1) fill on arrival—medication

4

delay (we are ordering the medication and will notify the patient when it is ready for pick up the
following business day), (2) prior authorization needed (the medication requires additional
insurance review/approval), (3) insurance issue (insurance on file expired, need new insurance
information to process prescription), (4) prescriber denial (prescriber denied refill request;
patient needs to contact provider), (5) prescription clarification (prescriber clarification needed
on prescription), (6) refill too soon (prescription is too soon to fill), (7) contact Specialty
Pharmacy (please contact Specialty Pharmacy at (402) 559-2484 to schedule your next refill), (8)
more information needed for medication assistance application, and (9) payment information on
file needs updated.
Literature Review:
In Mobile Health Medication Adherence and Blood Pressure Control in Renal Transplant
Recipients, this study assessed a prototype mobile health medication and blood pressure selfmanagement system for kidney transplant patients with uncontrolled hypertension
(McGillicuddy et. al, 2013). This study used an electronic medication tray on a mobile phone
application and received push notifications to remind them to take their various medications at
the varying times of the day. Participation and retention rates were 75% and 91%, respectively
(McGillicuddy et. al, 2013). The problems with the study were the small sample size (20
patients) and short time frame (3 months) and did not have any statistical measures of the effect
on medication adherence. My capstone project will provide a larger sample size, a longer time
frame, and using statistical measures to quantify using a mobile phone application and/or text
messaging service on medication adherence in solid organ transplant patients.
In Assessing Medication Adherence in Solid-Organ Transplant Recipients, this crosssectional, single-center, retrospective cohort study evaluated 225 lung, kidney, and liver
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transplant recipients’ adherence to immunosuppressant mediation based on dosages and
dispensing records using MPR and gaps in prescription refills (>30-day lapse between expected
depletion of supply and next refill) in assessing adherence for 2 years (Chun-Wei Su, 2013).
Overall, MPR was 95.4%, 95.9%, and 92.7% in lung, kidney, and liver recipients’ (Chun-Wei
Su, 2013). Only 7.1% of patients had a MPR lower than 80%, which was the cutoff for
nonadherence (Chun-Wei Su, 2013). Statistical analyses were not performed for factors of
nonadherence due to the small percentage of nonadherent patients. The problem with this study
was no statistical analysis was completed on population characteristics: age, gender, race, and
type of transplant. My capstone project with include statistical analysis of population
characteristics: age, gender, race, and type of transplant at baseline and 1-year post-intervention
in the form of average MPR, paired t-test, and multiple linear regression.
Data & Methods
A group of 82 patients that were voluntarily enrolled in the mobile phone application/text
messaging service before 6/12/2020 were identified via a report within the pharmacy software,
McKesson. Further analysis excluded two patients that were recently deceased, five pediatric
patients (< 19-years-old), and two bone marrow transplant patients. Pediatric patients were
excluded because a parent or guardian must still be involved in their healthcare which could
contribute to their medication adherence. Another 14 patients were excluded during initial data
analysis due to insufficient data due to switching pharmacies due to personal preference or
insurance requirements. With the above exclusions, the final study population included 59
patients. I built a custom Microsoft Excel report to include, medical record number, gender, race,
age, and type of transplant (lung, liver, heart, kidney, or combination). Next, I used Microsoft
Excel to enter each patient’s average individual MPR for immunosuppressant therapy (from
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McKesson patient profile data that was manually extracted) one year prior to text messaging or
mobile phone application intervention (6/12/2019-6/11/2020) and comparing that to their
average MPR 1 year post intervention (6/12/2020-6/11/2021). In this way, each patient acts as
their own comparator.
The MPR is the sum of the days’ supply for all fills of a given drug in a particular time
period, divided by the number of days in the time period (1 year). 2020 was a leap year, which
was accounted for in my calculations, by using 366 days as my denominator in the MPR
calculation (instead of 365 in a normal year). In a patient that is perfectly adherent to medication
therapy, the MPR would equal 100% or 1:1. MPR may be skewed if the patient is obtaining
medications earlier than needed which will make the ratio greater than 100%; in this study, the
cap was at 100% so it doesn’t skew other calculations such as further analysis based on
demographic information or transplant type.
The sample characteristics were examined and reported in terms of type of transplant,
sex, race, and age. Then t-tests were conducted to examine if MPR is associated with age, sex,
race, or type of transplant at baseline. Paired t-tests were conducted to examine differences in
MPR in the whole study sample and stratified samples by age, sex, race, and type of transplant
pre- and post- the intervention. In the end, a multiple linear regression was run to examine if
there were significant change in patient MPR over the two years after controlling age, sex, race,
and type of transplant in the model.
Results (See Appendix for Data Tables)
As shown in Table 1, my study population consisted primarily of kidney transplants (80%),
male gender (63%), white race (59%), and a close split of 40-59 year-olds (42%) and 60-79 year-
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olds (44%). Heart and combination transplants comprised each 7% of the study population.
While lung and liver transplants accounted for each 3% of the study population.
Table 2 shows group differences in MPR for 2019-2020 at baseline. The results showed that
lung and combination transplant patients had a higher level of MPR compared to patients with
other types of transplants (0.96 vs. 0.87, p=0.003) at baseline. Ages 20-59 had a higher level of
MPR compared to patients ages 60-0.99 (0.85 vs. 0.91, p=0.03) at baseline. There were no
statistically significant differences between patients with kidney transplants and patients with other
solid organ transplant types (0.87 vs.0.91, p=0.28), female patients and male patients (0.90 vs.
0.87, p=0.47), and white and other races (0.89 vs. 0.86, p=0.31).
Table 3 shows the study population by average MPR in 2019-2020 and 2020-2021,
difference in MPR in two years, and p-value for the paired t-tests comparing the difference in
MPR for the whole sample and by different groups over time. The average MPR for all 59 study
participants were 0.88 in year 2019-2020 and 0.86 in year 2020-2021. The results of the twotailed, paired t-test comparing the average MPR in year 2020-2021 to that of year 2019-2020
returned a p-value of 0.31, indicating no statistically significant differences between these two
years. This result does not support our hypothesis that the use of a mobile phone application
and/or text messaging service will increase the MPR of solid organ transplant patients. Pre-post
comparison was also conducted for different groups by transplant type, age, sex, and race. There
were no statistically significant differences in MPR between the two years for any of the groups
tested. For lung and combination transplant patients the average MPR was 0.96 in 2019-2020
and 0.88 in 2020-2021, the differences were not statistically significant (change= -0.08, p=0.24).
Patient with other types of transplants showed an average MPR of 0.87 for 2019-2020 and 0.86
for 2020-2021, the differences were not statistically significant (change= -0.01, p=0.56). Patients
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of the white race had an average MPR of 0.89 in 2019-2020 and 0.89 and 2020-2021, however,
the differences were not statistically significant (change=0, p=0.68). Patients of other races had
an average MPR of 0.86 for 2019-2020 and 0.83 for 2020-2021, however, the differences were
not statistically significant (change= -0.03, p=0.34). For female patients, the average MPR was
0.90 for 2019-2020 and 0.87 for 2020-2021, the differences were not statistically significant
(change= -0.03, p=0.21). For male patients, the average MPR was 0.87 for 2019-2020 and 0.86
for 2020-2021, the differences were not statistically significant (change= -0.01, p=0.73). For
patients aged 60-99 years-old, the average MPR was 0.91 in year 2019-2020 and 0.93 in year
2020-2021, however, the differences were not statistically significant (change=0.02, p=0.53). 2059 years-old patients the average MPR was 0.85 in year 2019-2020 and 0.81 in 2020-2021,
however, the differences were not statistically significant (change= -0.04, p=0.14).
The results of linear regression analysis are to test the year differences after controlling age,
sex, race, and types of transplant are shown in Table 4. The outcome variable is the level of MPR
for all participants. Type of transplant was categorized in two groups: other transplants vs. lung
& combination (reference group). Race was categorized in two groups: other vs. white (reference
group). Sex was categorized in two groups: male and female (reference group). Age was
categorized in two groups: age 20-59 (reference group) vs. 60-99 years-old. No statistically
significant association was found between year and MPR (coefficient= -0.02, p=0.52) after
controlling for transplant type, race, sex, and age. The result does not support our hypothesis that
the use of a mobile phone application and/or text messaging service will increase the MPR of
solid organ transplant patients. There was a statistically significant difference for the age
covariable (coefficient=0.091, p=0.0009). The average MPR for patients aged 60-99 years was
0.091 higher compared to patients aged 20-59 years after controlling for other variables in the
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model. There was no statistically significant association and type of transplant (lung and
combination vs. other transplants) (coefficient=0.05, p=0.16), race (coefficient= -0.05, pvalue=0.10), or sex (coefficient= -0.02, p-value=0.51) over the two years.
Discussion
The results of this study did not support my hypothesis of an overall positive association
between the use of a mobile phone application and/or text messaging service and the MPR. This
could be due to the following limitations of MPR: MPR does not accurately measure medication
adherence to the extent that the patient is actually taking the medication as directed, it does
assess whether the patient has access to the drug to take as directed by the physician. In a patient
that is perfectly adherent to medication therapy, the MPR would equal 100% or 1. However, a
threshold of ≥0.80 is conventionally used to indicate optimal adherence (Tang et. al, 2017). In
this study, the average MPR in both years and for all categories was ≥0.80. It could be argued
that transplant patients should have a higher baseline MPR than other patients due to the
continued education they receive from medical providers about the importance of medication
adherence to immunosuppressant medications and the survival of their graft. Additionally, it
would have been interesting to analyze as an additional covariable how much time has passed
since transplantation for each patient. Theoretically, a patient may be more adherent to
medication therapy immediately after transplantation due to more frequent office visits and lab
draws for immunosuppressant levels for dose adjustments. This study was also conducted in the
midst of the COVID-19 pandemic, and the effect this had is unknown, but should be
acknowledged. In conclusion, analyzing the effect of the same intervention on a larger patient
population with a lower baseline MPR, such as diabetic patients, would be more powerful using
the same pre-post study design.
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Group differences at baseline MPR indicated a statistically significant finding in both lung &
combo transplants when compared to other transplants and age 20-59 when compared to age 6099. However, the sample size of lung & combo transplants was small at just 6 participants. In
practice, lung and combination transplants are less frequently conducted, on average, compared to
kidney transplants; for example, so a larger sample size of these specific transplant types would
be hard to achieve when compared with other types of transplants. A multiple linear regression
analysis results did find a statistical difference between patient MPR and age even after controlling
for sex, race, year, and transplant types. Patients in 60-99 age group may have better adherence
due to more extensive screening for medical clearance prior to transplant listing due to higher risk
for surgery or closer post-transplant follow-up, potentially better health literacy and health habits,
and more family/home health worker involvement in older adults post-transplant.
The strengths of this study included: length of study (2 years) and using statistical measures
to quantify medication adherence (MPR). When compared to Mobile Health Medication
Adherence and Blood Pressure Control in Renal Transplant Recipients consisted of 20 patients,
a 3-month time period, and no statistical measures to quantify medication adherence
(McGillicuddy et. al, 2013). This prototype system studied by McGillicuddy et. al, of using push
notifications on a mobile phone application to remind them to take their various medications at
varying times of the day appeared to be safe, highly acceptable, and useful to patients and
providers to promote medication adherence. When compared to Assessing Medication Adherence
in Solid-Organ Transplant Recipients, the study population consisted of 225 patients, was 2
years in length, but did not do a quantitative analysis due to over 90% of patient population
having an average MPR ≥0.80. My study limitations are a pre-post design, small sample size,
and using Microsoft Excel for data analysis. Without a control group the true impact of these
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interventions is not accurately captured by the pre-post comparison. The sample size of our study
could still be too small to effectively detect the effect of the intervention on MPR of the patients
studied. Finally, Microsoft Excel is difficult to use and less powerful when compared to SPSS
for performing data analysis.
The results of this study continue to shed light on the complexity of medication adherence
and the many factors that play into it. It is difficult to compare adherence rates of one patient to
another without taking into account the various factors that may impact adherence such as:
convenience (text messaging/mobile phone application), cost, environment, and health literacy to
name a few. The best way to improve future studies on the impact of Nebraska Medicine
Outpatient Pharmacy’s Text Messaging/Mobile Phone Application is to increase patient
enrollment by continuing to spread the word to not only patients with promotional materials, but
also, enlist the help of other healthcare professionals (like Transplant Pharmacists) to promote
the service and use this technology as a tool in their toolbelt to continue to improve medication
adherence which my study ultimately did. In addition, a randomized controlled trial, conducting
multiple regression to control for other factors of adherence (cost, socioeconomic status, and
health literacy), and using SPSS statistical software for data analysis would be beneficial in
future studies with a larger patient population to further assess the benefit of technology to
promote medication adherence in solid organ transplant recipients.
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Application of Public Health Competencies:
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1. MPHF3: Analyze quantitative and qualitative data using biostatistics, informatics,
computer-based programming and software, as appropriate.
i. My capstone incorporated the above foundational competency by
analyzing data using the McKesson pharmacy software data to determine
each patient’s average MPR, paired t-test, and linear regression using
Microsoft Excel before and after intervention of text messaging/mobile
phone application.
2. HSRAMPH5: Examine information about health policy issues and problems, and
evaluate alternative policy options for these issues.
ii. My capstone incorporated the above concentration competency by
drawing conclusions after analyzing the data on how to better utilize
technology to improve medication adherence in solid organ transplant
patients that fill their medications at the Nebraska Medicine Outpatient
Pharmacy to get a larger patient population to study more accurately the
impact this program is having by possibly doing a randomized controlled
trial or calculating multiple regression analysis.
3. HSRAMPH1: Demonstrate the skills to analyze and resolve organizational issues
through a multidisciplinary systems-based approach.
iii. My capstone incorporated the above concentration competency by
presenting information to the Transplant team pharmacists at Nebraska
Medicine with the findings of my Capstone Project before the end of the
Spring semester (before my presentation) to promote patients to use the
Nebraska Medicine Outpatient Pharmacy for the filling of their
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medications which includes a free mobile phone application/text
messaging service. Additionally, in order to create the custom report
within the pharmacy software, McKesson, to identify a specific subset of
transplant patients that had downloaded the app and/or using the text
messaging software and had voluntarily opted-in before 6/12/2020 I
worked with a team with representatives from McKesson and IT, 340B
Analysts, and Pharmacy Management at Nebraska Medicine. I tried to
resolve the issue of medication nonadherence that increases healthcare
expenditures to the organization, by showing a possible benefit of the new
mobile phone application and/or text messaging service that the Nebraska
Medicine Outpatient Pharmacy had recently implemented could increase
medication adherence in a high-risk group of patients, solid organ
transplant recipients.
Supervision and Facilities:
Allison Beachler—Pharmacist Lead at Nebraska Medicine Outpatient Pharmacy at Durham
Outpatient Center; (402) 559-5215

Human Subjects:
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After consultation with UNMC IRB, my project is considered a Quality Improvement Project
which does not require an application to the IRB, and I am allowed to publish my findings as
well without approval.
Appendix
Table 1: Study Population Breakdown by Type of Transplant, Sex, Race, and Age for 59
Participants
Characteristics
Type of Transplant
Heart
Lung
Liver
Kidney
Combination
Sex
Female
Male
Race
American Indian/Alaskan
Native
Native Hawaiian or Other
Pacific Islander
Black
Hispanic
Asian
White
Age
20-39
40-59
60-79
80-99

N

Percent

4
2
2
47
2

6.78
3.39
3.39
79.66
6.78

22
37

37.29
62.71

3

5.08

2

3.40

13
5
1
35

22.03
8.48
1.69
59.32

7
25
26
1

11.86
42.38
44.07
1.69
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Table 2: Group Differences at Baseline MPR (2019-2020)
Group

N

Average MPR

Kidney Transplant

47

0.87

Other Solid Organ Transplant Types

12

0.91

Lung & Combo Transplant

6

0.96

Other Transplant Types

53

0.87

Female

22

0.90

Male

37

0.87

White Race

35

0.89

Other Races

24

0.86

Ages 20-59

32

0.85

Ages 60-99

27

0.91

P-Value
0.28

0.003

0.47

0.31

0.03
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Table 3: Average MPR of the Study Participants and by Transplant Type, Race, Gender, Age
Groups Over Two Years

N

Average MPR
in 2019-2020
0.88

Average MPR
in 2020-2021
0.86

Difference in
MPR
-0.02

0.31

0.96

0.88

-0.08

0.24

Other 53

0.87

0.86

-0.01

0.56

White 35

0.89

0.89

0

0.68

Other 24

0.86

0.83

-0.03

0.34

Female 22

0.90

0.87

-0.03

0.21

Male 37

0.87

0.86

-0.01

0.73

20-59 32

0.85

0.81

-0.04

0.14

60-99 27

0.91

0.93

0.02

0.53

Total Sample
59
Type of
Transplant
Lung & Combo 6

P-Value

Race

Sex

Age
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Table 4: Linear Regression of Average MPR for Years 2019-2020 & 2020-2021
Variable

Coefficient

P-Value

Type of Transplant
(Lung & Combo vs.
Other)
Race (White vs. Other)

0.05

0.16

-0.05

0.10

Sex (Female vs. Male)

-0.02

0.51

Age (20-59 vs. 60-99)

0.091

0.0009

Year (2019-2020 vs.
2020-2021)

-0.02

0.52

19

